Biomedical subjects

I A Samylina

Publications and source records attributed to I A Samylina.

6 recordsLinked to original sources

PubMed2004

[Food supplements and medicines of vegetative origin. Safety estimation and standardization].

The article describes the modern legislative and normative base of both Russian made and foreign made food supplements turnover. The main requirements to them. The reasons for banning the use of some particular ingredients in food supplements formula are substantiated. The ways of improving the normative base for food supplements as well as for medicines of vegetative origin are proposed. The conclusion is made, that this base is more perfect than for the medicines, produced from herbs.

Consumer Product Safety↗

PubMed2001

[Experience in using phytopreparations to prevent and correct inflammatory urinary tract diseases].

The waste of some fruits, berries, and vegetables, which are accumulated by food industries (juice-extracting, wine, confectionery, and other industries) and generally completely utilized was pharmacognistically and phytochemically analyzed. The phytochemical analysis showed that the study objects (black currant, raspberry, viburnum, red and black mountain ashes, and grape fruit bagasses and melon, squash, and tomato seeds) contain a lot of lipophilic fractions (fatty oil) that present a complex of valuable biologically active substances. The developed recipes of phytopreparations are safe-and-easy-to-use and can be successfully used in patients with chronic inflammatory uterine appendage diseases and in those who present a difficult cohort of patients with lower urinary tract dysfunctions which are hardly correctable and require sophisticated choice of adequate drug therapy.

Anti-Infective Agents↗

PubMedDate not supplied

[A trial of the preparation Cheblin-SK-1 in models of nematodiases].

A kerosene milky-stage walnut (Juglans spp.) extract, a folk medication, has come into wide use in the past 30 years. The drug CK-I was prepared on a scientific basis. Its acute toxicity and toxicological profile were studied on albino mice and rats, chickens, chicken embryos, piglets. The maximum non-lethal dose of CK-I was 19 g/kg for albino mice and 21 g/kg for albino rats. The drug can be classified as i.v. hazard class. The anthelmintic effects of CK-I were examined in mice with cyphaciasis and in chickens with ascariasis and heterakiasis. In murine cyphaciasis, CK-I given in a dose of 75 mg/kg to albino mice provided 100% efficiency. Its doses of 800 and 1000 mg/kg were required to achieve this effect in chick ascariasis and heterakiasis, respectively.

Animals↗

PubMedDate not supplied

[Immunity induced by immunomodulators during echinococcal immunosuppression].

The echinococcal immunosuppression induced in experimental mice by a human parasite strain is accompanied by immunosuppression, whereby the administration of immunomodulants favors normalization of the cell and humoral immunity chains. Among a series of preparations studied, the best results were obtained for polyoxidonium: in the case of immunosuppression induced by cyclophosphan, polyoxidonium administration led normalization of the cell and humoral immunity and the phagocytosis of neutrophils and macrophages.

Adjuvants, Immunologic↗

PubMedDate not supplied

[Antimicrobial, echinococcidial and immunostimulating properties of the drug Cheblin-SK-1].

The antimicrobial properties of the drug Cheblin-CK-1 (CCK-1) were determined in mice intraabdominally inoculated with Proteus mirabilis-4691 in a dose of 140-200 million daily cultured microbial bodies. Its comparison agent was ampicillin. CCK-1 was found to act as an antibiotic similar to ampicillin in its effects. The antimicrobial activity of CCK-1 against Staphylococcus aureus and Escherichia coli isolated from the contents of echinococcal cysts from patients operated on was also established. Its echinococcidial activity was found in experiments on the cotton rats and piglets inocculated with echinococci. CCK-1 was also tested on volunteers. Before surgery, 186 patients with echinococcosis took the drug and 26 patients with the same disease did not and they served as controls. At first the drug suppressed the growth of parasitic larvocysts with destruction and death of 85-95% of germinal elements of larvocysts and then killed parasites. In patients receiving a complete course of its therapy, protein and amino acid metabolisms restored, followed by immunity recovery.

Animals↗

PubMedDate not supplied

[Experimental echinococcosis and alveococcosis and a trial of the preparation SK-1].

In autobred albino mice, the maximum nonlethal dose of the agent CK-1 was established, which was 19.0 g/kg, the agent was nontoxic. Cotton rats aged 30-45 days were infected by alveococcosis from a donor rat. The methods and formulas developed by Mikhaĭlitsin et al. were used during experiments and investigations. At the beginning of treatment, 5 rats were found to have a great deal of parasitic larvocysts (PL) 10 days after infection. Eight rats formed a control group, 8 were treated with CK-1 in a constantly increasing doses of 0.1, 0.26, and 0.34 g/kg for 3 weeks. Following 40 days of infection, the animals were anesthesized and CK-1 was ascertained to have a high antialveococcal activity: the index of suppressed PL growth was 90.23 to 92.74%. In 14 piglets aged 1 month, infected by echinococcosis strains and treated CK-1 in high doses, was established to cause echinococcal death. In 14 puppies, the agent was highly effective in strobular echinococcosis.

Animals↗